Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 928-541-6 | CAS number: 146939-27-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Justification for classification or non-classification
In the FDA Pharmacology review, with application number 20-825, for ziprasidone hydrochloride monohydrate the conclusion on "reproduction studies/pregnancy labeliing" are detailed below.
"Although the sponsor has recommended Pregnancy Category C labeling based on increased numbers of rat pups born dead and decreased postnatal survival, there is no mention of teratogenic effects. However, it is the opinion of our reviewers that there is sufficient evidence to consider ziprasidone to be a teratogen in rabbits even though none of the three teratogenicity studies conducted in that species would technically be considered a definitive one. In the first study (doses of 10, 30 and 60 mg/kg/day during organogenesis there were not enough litters/fetuses available to evaluate due to a combination of dam mortality, reduced pregnancy rate and decreased viable litters. The study was repeated twice; once with two dose groups (10 and 30 mg/kg/day) and once with one dose group (30 mg/kg/day) rather than the usual three dose groups. However, in the first of those studies, ventricular septal defects associated with other cardiac defects occurred in 3 high dose fetuses from 3 different litters. In the second study, ectopic kidneys were observed, also in 3 fetuses from 3 different litters. These malformations were not associated with clear evidence for maternal toxicity, indicating a potentially direct effect on the fetus, and the incidences fell outside the historical control range for the particular strain/laboratory/time period.
The fact that the findings were in each case from 3 separate litters adds strength to the signal. We have therefore concluded that ziprasidone is teratogenic in rabbits and have included the findings, which occurred at only 3 times the maximum 'recommended daily human dose on a surface area basis, in the pregnancy section of labeling, retaining the "C" category.
Teratogenicity was not observed in the rat study."
However, from the document is not well clear if the malformations observed in rabbits were not associated with clear evidence for maternal toxicity. Moreover, teratogenicity was not observed in the rat study; so an by an overall evaluation on the available information and the criteria of Annex I of CLP Regulation data are inconclusive for the classification of the substance.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
